Treatment of subclinical hypothyroidism questioned in controversial new guidance

GPs should monitor patients with subclinical hypothyroidism instead of prescribing thyroid hormones, according to a controversial new clinical practice guideline that could 'substantially alter prescribing trends'.

An expert panel has concluded that very few adults with subclinical hypothyroidism benefit from treatment with thyroid hormones. | GETTY IMAGES
An expert panel has concluded that very few adults with subclinical hypothyroidism benefit from treatment with thyroid hormones. | GETTY IMAGES

The guideline, published in the BMJ, was triggered by a systematic review of randomised controlled trials which showed that hormone treatment did not improve quality of life or symptoms in patients with subclinical hypothyroidism.

In light of this finding, the guideline panel of clinicians, methodologists and patients recommended against routinely prescribing thyroid hormones in adults with elevated TSH levels and normal free T4 (thyroxine) levels.

However, in a joint statement published on 29th May, the Society for Endocrinology and the British Thyroid Association rejected the panel's recommendation. The bodies expressed concern that patients with subclinical hypothyroidism could miss out on vital treatment if their condition progresses, as a result of the panel's 'over-extrapolation of data, most of which is from older patients with milder symptoms or from small-scale studies'.

Current guidelines generally recommend thyroid hormones for adults with TSH levels >10mIU/L and for people with lower TSH values who are young, symptomatic, or have specific indications for prescribing. Research shows that the prevalence of hormone treatment for subclinical hypothyroidism doubled in the decade between 1996 and 2006.

The systematic review that informed the BMJ guideline included 21 trials with 2192 participants. The reviewers concluded that thyroid hormones consistently demonstrated no clinically relevant benefits on quality of life or thyroid-related symptoms (including depression, fatigue, and BMI) in patients with subclinical hypothyroidism. Lower-quality evidence suggested that thyroid hormones may have little or no effect on cardiovascular events or mortality.

The panel's recommendation does not apply to women who are trying to become pregnant or patients with TSH >20 mIU/L. It may not apply to patients with severe symptoms or young adults (such as those ≤30 years old).

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Novel MS drug gains NICE approval

Novel MS drug gains NICE approval

New NICE guidance recommends ocrelizumab (Ocrevus)...

Drug shortages - live tracker

Drug shortages - live tracker

Check on the latest drug supply issues with MIMS' shortages...

Emollients, Potential Skin Sensitisers as Ingredients

Emollients, Potential Skin Sensitisers as Ingredients

Potential sensitising agents in emollient preparations.

NICE recommends new triple therapy option for diabetes

NICE recommends new triple therapy option for diabetes

Ertugliflozin (Steglatro) can now be prescribed routinely...